Reduction in lipopolysaccharide-induced thrombocytopenia by triflavin in a rat model of septicemia

Joen-Rong Sheu, Wei C. Hung, Ching-Hsiang Wu, Ming Chieh Ma, Ya Chen Kan, Chien-Huang Lin, Ming Shyan Lin, Hsiung N. Luk, Mao Hsiung Yen

Research output: Contribution to journalArticle

76 Citations (Scopus)

Abstract

Background - Thrombocytopenia frequently occurs early in the course of Gram-negative bacterial infections. Triflavin, an Arg-Gly-Asp-containing disintegrin, has been suggested to interfere with the interaction of fibrinogen with the glycoprotein IIb/IIIa complex. The present study was undertaken to determine whether triflavin could prevent thrombocytopenia in lipopolysaccharide (LPS)-treated rats. Methods and Results - In this study, 51Cr-labeled platelets were used to assess blood and tissue platelet accumulation after LPS challenge. The administration of LPS (4 mg/kg IV bolus) for 4 hours induced a reduction in radiolabeled platelets in blood and an obvious accumulation of platelets in liver. Triflavin (500 μg/kg) but not GRGDS (20 mg/kg) significantly prevented the alteration of radiolabeled platelet distribution in blood and liver when induced by LPS. Furthermore, triflavin but not GRGDS markedly suppressed the elevation in plasma thromboxane B2 concentration within the 4-hour period of LPS administration. In LPS-treated rats, the 5-hydroxytryptamine level was lower in the blood and higher in the liver compared with levels in normal saline-treated rats. Pretreatment with triflavin (500 μg/kg) significantly reversed the 5- hydroxytryptamine concentration in blood and liver of LPS-treated rats. In histological examinations and platelet adhesion assay, triflavin markedly inhibited the adhesion of platelets to subendothelial matrixes in vivo and in vitro. Conclusions - The results indicate that triflavin effectively prevents thrombocytopenia, possibly through the following 2 mechanisms: (1) Triflavin markedly inhibits platelet aggregation, resulting in decreased thromboxane A2 formation. (2) It inhibits the adhesion of platelets to subendothelial matrixes, thereby leading to a reversal in the distribution of platelets in blood and liver in LPS-treated rats.

Original languageEnglish
Pages (from-to)3056-3062
Number of pages7
JournalCirculation
Volume99
Issue number23
Publication statusPublished - Jun 15 1999

Fingerprint

Thrombocytopenia
Lipopolysaccharides
Sepsis
Blood Platelets
glycyl-arginyl-glycyl-aspartyl-serine
Liver
Serotonin
Gram-Negative Bacterial Infections
Disintegrins
triflavin
Thromboxane B2
Platelet Glycoprotein GPIIb-IIIa Complex
Thromboxane A2
Platelet Aggregation
Fibrinogen

Keywords

  • Peptides
  • Platelet aggregation inhibitors
  • Platelets
  • Thromboxane

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine

Cite this

Reduction in lipopolysaccharide-induced thrombocytopenia by triflavin in a rat model of septicemia. / Sheu, Joen-Rong; Hung, Wei C.; Wu, Ching-Hsiang; Ma, Ming Chieh; Kan, Ya Chen; Lin, Chien-Huang; Lin, Ming Shyan; Luk, Hsiung N.; Yen, Mao Hsiung.

In: Circulation, Vol. 99, No. 23, 15.06.1999, p. 3056-3062.

Research output: Contribution to journalArticle

Sheu, J-R, Hung, WC, Wu, C-H, Ma, MC, Kan, YC, Lin, C-H, Lin, MS, Luk, HN & Yen, MH 1999, 'Reduction in lipopolysaccharide-induced thrombocytopenia by triflavin in a rat model of septicemia', Circulation, vol. 99, no. 23, pp. 3056-3062.
Sheu, Joen-Rong ; Hung, Wei C. ; Wu, Ching-Hsiang ; Ma, Ming Chieh ; Kan, Ya Chen ; Lin, Chien-Huang ; Lin, Ming Shyan ; Luk, Hsiung N. ; Yen, Mao Hsiung. / Reduction in lipopolysaccharide-induced thrombocytopenia by triflavin in a rat model of septicemia. In: Circulation. 1999 ; Vol. 99, No. 23. pp. 3056-3062.
@article{cacf7f7f3ab14b149c72767f3ab65ddc,
title = "Reduction in lipopolysaccharide-induced thrombocytopenia by triflavin in a rat model of septicemia",
abstract = "Background - Thrombocytopenia frequently occurs early in the course of Gram-negative bacterial infections. Triflavin, an Arg-Gly-Asp-containing disintegrin, has been suggested to interfere with the interaction of fibrinogen with the glycoprotein IIb/IIIa complex. The present study was undertaken to determine whether triflavin could prevent thrombocytopenia in lipopolysaccharide (LPS)-treated rats. Methods and Results - In this study, 51Cr-labeled platelets were used to assess blood and tissue platelet accumulation after LPS challenge. The administration of LPS (4 mg/kg IV bolus) for 4 hours induced a reduction in radiolabeled platelets in blood and an obvious accumulation of platelets in liver. Triflavin (500 μg/kg) but not GRGDS (20 mg/kg) significantly prevented the alteration of radiolabeled platelet distribution in blood and liver when induced by LPS. Furthermore, triflavin but not GRGDS markedly suppressed the elevation in plasma thromboxane B2 concentration within the 4-hour period of LPS administration. In LPS-treated rats, the 5-hydroxytryptamine level was lower in the blood and higher in the liver compared with levels in normal saline-treated rats. Pretreatment with triflavin (500 μg/kg) significantly reversed the 5- hydroxytryptamine concentration in blood and liver of LPS-treated rats. In histological examinations and platelet adhesion assay, triflavin markedly inhibited the adhesion of platelets to subendothelial matrixes in vivo and in vitro. Conclusions - The results indicate that triflavin effectively prevents thrombocytopenia, possibly through the following 2 mechanisms: (1) Triflavin markedly inhibits platelet aggregation, resulting in decreased thromboxane A2 formation. (2) It inhibits the adhesion of platelets to subendothelial matrixes, thereby leading to a reversal in the distribution of platelets in blood and liver in LPS-treated rats.",
keywords = "Peptides, Platelet aggregation inhibitors, Platelets, Thromboxane",
author = "Joen-Rong Sheu and Hung, {Wei C.} and Ching-Hsiang Wu and Ma, {Ming Chieh} and Kan, {Ya Chen} and Chien-Huang Lin and Lin, {Ming Shyan} and Luk, {Hsiung N.} and Yen, {Mao Hsiung}",
year = "1999",
month = "6",
day = "15",
language = "English",
volume = "99",
pages = "3056--3062",
journal = "Circulation",
issn = "0009-7322",
publisher = "Lippincott Williams and Wilkins",
number = "23",

}

TY - JOUR

T1 - Reduction in lipopolysaccharide-induced thrombocytopenia by triflavin in a rat model of septicemia

AU - Sheu, Joen-Rong

AU - Hung, Wei C.

AU - Wu, Ching-Hsiang

AU - Ma, Ming Chieh

AU - Kan, Ya Chen

AU - Lin, Chien-Huang

AU - Lin, Ming Shyan

AU - Luk, Hsiung N.

AU - Yen, Mao Hsiung

PY - 1999/6/15

Y1 - 1999/6/15

N2 - Background - Thrombocytopenia frequently occurs early in the course of Gram-negative bacterial infections. Triflavin, an Arg-Gly-Asp-containing disintegrin, has been suggested to interfere with the interaction of fibrinogen with the glycoprotein IIb/IIIa complex. The present study was undertaken to determine whether triflavin could prevent thrombocytopenia in lipopolysaccharide (LPS)-treated rats. Methods and Results - In this study, 51Cr-labeled platelets were used to assess blood and tissue platelet accumulation after LPS challenge. The administration of LPS (4 mg/kg IV bolus) for 4 hours induced a reduction in radiolabeled platelets in blood and an obvious accumulation of platelets in liver. Triflavin (500 μg/kg) but not GRGDS (20 mg/kg) significantly prevented the alteration of radiolabeled platelet distribution in blood and liver when induced by LPS. Furthermore, triflavin but not GRGDS markedly suppressed the elevation in plasma thromboxane B2 concentration within the 4-hour period of LPS administration. In LPS-treated rats, the 5-hydroxytryptamine level was lower in the blood and higher in the liver compared with levels in normal saline-treated rats. Pretreatment with triflavin (500 μg/kg) significantly reversed the 5- hydroxytryptamine concentration in blood and liver of LPS-treated rats. In histological examinations and platelet adhesion assay, triflavin markedly inhibited the adhesion of platelets to subendothelial matrixes in vivo and in vitro. Conclusions - The results indicate that triflavin effectively prevents thrombocytopenia, possibly through the following 2 mechanisms: (1) Triflavin markedly inhibits platelet aggregation, resulting in decreased thromboxane A2 formation. (2) It inhibits the adhesion of platelets to subendothelial matrixes, thereby leading to a reversal in the distribution of platelets in blood and liver in LPS-treated rats.

AB - Background - Thrombocytopenia frequently occurs early in the course of Gram-negative bacterial infections. Triflavin, an Arg-Gly-Asp-containing disintegrin, has been suggested to interfere with the interaction of fibrinogen with the glycoprotein IIb/IIIa complex. The present study was undertaken to determine whether triflavin could prevent thrombocytopenia in lipopolysaccharide (LPS)-treated rats. Methods and Results - In this study, 51Cr-labeled platelets were used to assess blood and tissue platelet accumulation after LPS challenge. The administration of LPS (4 mg/kg IV bolus) for 4 hours induced a reduction in radiolabeled platelets in blood and an obvious accumulation of platelets in liver. Triflavin (500 μg/kg) but not GRGDS (20 mg/kg) significantly prevented the alteration of radiolabeled platelet distribution in blood and liver when induced by LPS. Furthermore, triflavin but not GRGDS markedly suppressed the elevation in plasma thromboxane B2 concentration within the 4-hour period of LPS administration. In LPS-treated rats, the 5-hydroxytryptamine level was lower in the blood and higher in the liver compared with levels in normal saline-treated rats. Pretreatment with triflavin (500 μg/kg) significantly reversed the 5- hydroxytryptamine concentration in blood and liver of LPS-treated rats. In histological examinations and platelet adhesion assay, triflavin markedly inhibited the adhesion of platelets to subendothelial matrixes in vivo and in vitro. Conclusions - The results indicate that triflavin effectively prevents thrombocytopenia, possibly through the following 2 mechanisms: (1) Triflavin markedly inhibits platelet aggregation, resulting in decreased thromboxane A2 formation. (2) It inhibits the adhesion of platelets to subendothelial matrixes, thereby leading to a reversal in the distribution of platelets in blood and liver in LPS-treated rats.

KW - Peptides

KW - Platelet aggregation inhibitors

KW - Platelets

KW - Thromboxane

UR - http://www.scopus.com/inward/record.url?scp=0033564062&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033564062&partnerID=8YFLogxK

M3 - Article

VL - 99

SP - 3056

EP - 3062

JO - Circulation

JF - Circulation

SN - 0009-7322

IS - 23

ER -